TY - JOUR
T1 - Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer
AU - Lorusso, Domenica
AU - Ceni, Valentina
AU - Muratore, Margherita
AU - Salutari, Vanda
AU - Nero, Camilla
AU - Pietragalla, Antonella
AU - Ciccarone, Francesca
AU - Carbone, Vittoria
AU - Daniele, Gennaro
AU - Scambia, Giovanni
N1 - Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Introduction: In recent years, ovarian cancer (OC) treatment has been enriched with many new target therapies, most of all antiangiogenic drugs and PARP inhibitors (PARPis), which have literally changed the natural history of the disease. The impressive results of immunotherapy in other malignancies, mainly melanoma and lung cancer, and the good signals of activity in gynecological neoplasms like cervical and microsatellite instable (MSI-H) endometrial cancer, opened the space to the introduction of immune-stimulatory drugs in ovarian cancer. Area covered: The goal of this article is to summarize the newest evidence on the use of immune check point inhibitors in OC trying to explain why, at present, this strategy has failed to improve clinical outcome and focusing on the possible strategies to overcome treatment failure. Expert opinion: Although numerous trials have been undertaken, only scanty results have been obtained so far with immune check-point inhibitors (ICIs) in OC either when used as single agents or in combination with antiangiogenic therapy and ongoing trials are exploring the association of ICIs with PARPis and other ICIs. A better knowledge of predictive biomarkers of response and mechanisms of immunotherapy resistance, will help in identifying the most appropriate population to treat with ICIs.
AB - Introduction: In recent years, ovarian cancer (OC) treatment has been enriched with many new target therapies, most of all antiangiogenic drugs and PARP inhibitors (PARPis), which have literally changed the natural history of the disease. The impressive results of immunotherapy in other malignancies, mainly melanoma and lung cancer, and the good signals of activity in gynecological neoplasms like cervical and microsatellite instable (MSI-H) endometrial cancer, opened the space to the introduction of immune-stimulatory drugs in ovarian cancer. Area covered: The goal of this article is to summarize the newest evidence on the use of immune check point inhibitors in OC trying to explain why, at present, this strategy has failed to improve clinical outcome and focusing on the possible strategies to overcome treatment failure. Expert opinion: Although numerous trials have been undertaken, only scanty results have been obtained so far with immune check-point inhibitors (ICIs) in OC either when used as single agents or in combination with antiangiogenic therapy and ongoing trials are exploring the association of ICIs with PARPis and other ICIs. A better knowledge of predictive biomarkers of response and mechanisms of immunotherapy resistance, will help in identifying the most appropriate population to treat with ICIs.
KW - Check-point inhibitors
KW - immunotherapy
KW - ovarian cancer
KW - PARP inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85092898972&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092898972&partnerID=8YFLogxK
U2 - 10.1080/14728214.2020.1836155
DO - 10.1080/14728214.2020.1836155
M3 - Review article
C2 - 33040627
AN - SCOPUS:85092898972
VL - 25
SP - 445
EP - 453
JO - Expert Opinion on Emerging Drugs
JF - Expert Opinion on Emerging Drugs
SN - 1472-8214
IS - 4
ER -